Mayo Clinic Parkinson’s Disease Study Tests an Unusual Approach to Brain Inflammation

By Emily Carter | Health & Science Correspondent

Publication date: October 23, 2026

Mayo Clinic researchers are investigating whether carefully targeted, ultra-low-dose radiation can influence inflammation in the brains of people with early-stage Parkinson’s disease. The clinical trial explores an unusual use for radiation, which is more commonly associated with cancer treatment.

The researchers are not using radiation to destroy brain tissue. Instead, they want to learn whether very low doses can affect biological processes linked to Parkinson’s disease and whether those changes might justify further study.

The Mayo Clinic Parkinson’s disease study remains experimental. It has not established that low-dose radiation improves symptoms, prevents the loss of brain cells, or slows the disease. Those questions are central to the investigation, not conclusions researchers can draw before the results are available.

Why researchers are studying inflammation in Parkinson’s disease

Parkinson’s disease is a progressive neurological disorder that affects movement and can also affect sleep, mood, thinking and other functions. Common symptoms include tremors, muscle stiffness, slowed movement and problems with balance. Symptoms and their progression vary from person to person.

Many symptoms are associated with the loss or damage of nerve cells that produce dopamine, a chemical messenger involved in controlling movement. These cells are concentrated in a brain region called the substantia nigra. As dopamine levels fall, the brain has more difficulty coordinating smooth, purposeful movements.

Parkinson’s disease is also associated with abnormal deposits of a protein called alpha-synuclein. These deposits, known as Lewy bodies when found inside cells, are part of the disease’s biology. Scientists continue to investigate how protein accumulation, cellular stress, genetic factors and environmental influences interact.

Inflammation is another area of research. In the brain, immune cells and signaling molecules help respond to injury and other threats. But when inflammatory activity becomes persistent or poorly regulated, it may contribute to damage in some neurological conditions.

Researchers are examining whether inflammatory processes help drive or worsen aspects of Parkinson’s disease. That does not mean inflammation is the sole cause of the condition, or that reducing it will necessarily improve a patient’s health. The relationship is complex, and researchers still need evidence to determine which processes matter most and when.

How the low-dose radiation clinical trial is designed

Mayo Clinic’s trial investigates whether ultra-low-dose radiation can influence inflammation in carefully selected areas of the brain. This differs from conventional radiation therapy, which generally uses higher doses to damage cancer cells or prevent them from growing.

For this study, the goal is not to destroy tissue. Investigators are testing whether a much lower radiation dose can produce measurable biological changes in targeted brain regions. Whether it can do so safely, consistently and in a way that matters clinically remains unknown.

Treatment planning uses magnetic resonance imaging, or MRI, alongside dopamine transporter imaging known as DaT-SPECT. MRI provides detailed pictures of brain anatomy, while DaT-SPECT helps assess dopamine transporter activity. Together, the scans help researchers identify and plan the treatment area.

The trial uses a medical linear accelerator, a machine that delivers precisely planned radiation. Mayo Clinic describes a technique called dynamic conformal arc therapy, which shapes radiation delivery around the intended target. The treatment is directed at selected areas rather than exposing the entire brain.

According to Mayo Clinic’s study description, participants receive five treatments, with one session each day over five consecutive days. Each session is reported to take about 10 to 15 minutes. That short treatment time does not, by itself, establish that the procedure is risk-free.

Researchers also collect blood samples and conduct clinical assessments. These measures are designed to help investigators examine biological signals and track changes in participants’ physical, cognitive and emotional symptoms over time.

Who may qualify, and where is the trial taking place?

The clinical-trial listing identifies Mayo Clinic in Rochester, Minnesota, as the study location. Its current status is listed as enrolling by invitation, meaning the trial is not presented as a treatment that is broadly available to anyone who requests it.

The registry lists a planned enrollment of 20 participants. The study is intended for people with early-stage Parkinson’s disease without a known genetic cause or predisposition. Its listed criteria also include a diagnosis made by a movement-disorder neurologist, a dopamine transporter scan confirming one-sided disease, and a score of 2 or lower on the modified Hoehn and Yahr scale, which measures disease severity.

The registry’s current eligibility criteria specify participants ages 45 through 70. Mayo Clinic’s public announcement, published October 21, describes an age range of 45 to 75. Because these official descriptions differ, prospective participants should confirm the current requirements directly with the study team rather than rely on either age range alone.

Other listed criteria address a person’s ability to complete assessments and follow-up imaging, provide informed consent and supply blood samples. The registry also lists exclusions, including a dementia diagnosis or concerns about another memory disorder, recent Parkinson’s medication changes, and radiation treatment for Parkinson’s disease received outside Mayo Clinic in Rochester. The research team determines eligibility under the full protocol.

What researchers will measure during follow-up

The study is designed to examine more than whether participants feel different after treatment. Researchers plan to assess inflammatory biomarkers, which are measurable signs of biological activity, and investigate changes related to abnormal protein accumulation.

Investigators will also use imaging to assess dopamine-related findings and monitor physical, cognitive and emotional symptoms. Mayo Clinic’s announcement describes assessments of biological markers shortly after treatment, followed by evaluations at three, six and 12 months.

These measurements could help researchers identify whether the treatment produces biological signals worth investigating further. They may also help show whether the approach is practical enough to study in a larger group.

But a change in a blood marker or scan is not the same as proof that a treatment slows Parkinson’s disease. Researchers would need to establish whether any observed changes are reliable, whether they translate into meaningful benefits for patients, and how long any effects last.

What the study cannot prove yet

The trial is an early investigation with a planned enrollment of just 20 people. A study of this size can help researchers explore a new approach and identify questions for later research. It is not large enough, on its own, to establish that the treatment works for the broader population of people with Parkinson’s disease.

Because the study does not include a separate comparison group in its listed design, interpreting changes over time may also be challenging. Symptoms can fluctuate, and participants may respond differently for reasons unrelated to the treatment. Further research would be needed to determine how much any observed change can be attributed to radiation.

Researchers must also evaluate safety, the duration of any biological effects and whether results justify a larger trial. Larger and appropriately controlled studies, along with longer-term monitoring, may be needed before scientists can determine whether the approach has a meaningful role in Parkinson’s care.

As of the latest available study information, the trial is an investigation of a possible treatment strategy, not evidence that low-dose radiation has been shown to slow or stop the disease. No results demonstrating that benefit have been established in the information reviewed for this report.

Potential risks require careful medical oversight

Radiation carries potential risks even when doses are low. The nature and likelihood of harm depend on factors such as the dose, the part of the body treated, the treatment plan and a patient’s individual circumstances.

The fact that radiation is targeted, or that each session is brief, does not remove the need for safety monitoring. A trial must assess possible adverse effects as well as potential biological benefits. The absence of established results should not be interpreted as proof that the approach is safe or effective.

Anyone approached about participating should ask the research team about the treatment plan, known and uncertain risks, follow-up requirements, alternatives and how safety will be monitored. Patients should also discuss participation with their treating neurologist, who can help put the experimental approach in the context of their individual care.

How this research fits with current Parkinson’s treatment

Current Parkinson’s care focuses on managing symptoms, preserving function and supporting quality of life. Treatment is individualized and may include medication, physical and occupational therapy, exercise, speech therapy and other supportive care.

Medicines such as levodopa can help address movement symptoms by increasing the brain’s available dopamine. Some patients may also be candidates for deep brain stimulation, a procedure that uses implanted electrodes to deliver electrical signals to specific brain areas. It can help manage certain symptoms in selected patients, but it is not a cure.

There is currently no established cure that stops Parkinson’s disease in all patients. That is one reason researchers are investigating different biological pathways, including inflammation. Still, an experimental approach should not be confused with a proven alternative to existing treatment.

For readers following other recent U.S. health developments, the same reporting principle applies: early findings and study announcements need to be distinguished from established medical guidance. Patients should not stop, reduce or replace prescribed Parkinson’s medication because of preliminary research or a news report.

What happens next?

The Mayo Clinic Parkinson’s disease study may help researchers learn whether ultra-low-dose radiation can affect biological processes associated with Parkinson’s disease. Its planned imaging, blood tests and follow-up assessments are intended to provide an initial picture of how the approach behaves in people with early-stage disease.

The key question is not simply whether a biological marker changes after treatment. Researchers must determine whether any change is meaningful, whether the treatment’s risks are acceptable and whether results can be reproduced in larger studies.

For now, low-dose radiation therapy for Parkinson’s disease remains experimental. The trial represents an effort to investigate a new research direction, but patients should continue to rely on established medical care while scientists work to determine whether this approach deserves further testing.

By Emily Carter | Health & Science Correspondent